Algorae Pharmaceuticals Limited
1AI
Pozycja w akcjach
#30907
Algorae Pharmaceuticals Limited, a company established in 1987 and based in... Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily conducts research and innovation in living cell technologies within New Zealand. Its development portfolio includes AI-116, a novel combination treatment pairing donepezil with cannabidiol, designed to address various forms of dementia, such as Alzheimer's disease. Another key candidate is AI-168, a unique blend of a cannabinoid and an existing, off-patent drug component, aimed at managing cardiovascular conditions like hypertension. Additionally, Algorae is progressing with NTCELL, an alginate-encapsulated product for the treatment of Parkinson's disease. The company is also collaborating with the University of New South Wales to create AlgaraeOS, an advanced drug discovery platform that utilizes artificial intelligence protocols and extensive data analytics to optimize drug identification and development processes.
Cena akcji
$0.00705285
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$14.30M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-30.71%
Kraj
AU
Handel Algorae Pharmaceuticals Limited (1AI)
Kategoria
Healthcare
Zyski dla Algorae Pharmaceuticals Limited (1AI)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Algorae Pharmaceuticals Limited, obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Algorae Pharmaceuticals Limited od 2026 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| Za mało danych dla podanych dat. | ||
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
